Apellis drops as disappointing Syfovre sales drive Q3 miss - MSN

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net …

7%
OFF

Apellis Dives As Worse-Than-Expected Syfovre Sales Add Fuel To …

1 week from now

But analysts called for $163 million to $167 million in sales, according to various reports. Sales fell 1.7% sequentially. This was Syfovre's first sequential decline since launching last year ...

msn.com

$50
OFF

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

1 week from now

Nov 2, 2023 · Syfovre sales beat our model estimate of $50 million. Apellis delivered more than 37,000 commercial vials and nearly 10,000 samples of Syfovre to doctors in the third quarter.

nasdaq.com

7%
OFF

Apellis Pharmaceuticals: Long-Term Growth Potential For Syfovre …

1 week from now

Nov 5, 2024 · The company’s drug, Syfovre, experienced a slight decline in sales for Q3, primarily due to increased gross-to-net adjustments that affected revenue, despite a 7% increase in …

businessinsider.com

$0.46
OFF

Apellis Pharmaceuticals, Inc. (APLS) Stock Earnings Dates & Report

1 week from now

Nov 8, 2024 · Apellis drops as disappointing Syfovre sales drive Q3 miss SA News Tue, Nov. 05 1 Comment Apellis Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of …

seekingalpha.com

$1500
OFF

Car Sales Of New Jersey Inc In Newark, NJ - Carsforsale.com®

1 week from now

Shop 31 vehicles for sale starting at $1,500 from Car Sales of New Jersey Inc, a trusted dealership in Newark, NJ. 471 Orange Street, Newark, NJ 07107. Get Directions.

carsforsale.com

20%
OFF

Apellis Stock Sell-off Over Syfovre Sales "overdone," Says Citi - MSN

1 week from now

The investment bank said Q1 sales of Apellis’s drug Syfovre beat the consensus estimate, but that “it appears the buyside expected more than an approximately 20% quarter-over-quarter …

msn.com

$162
OFF

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

1 week from now

Nov 6, 2024 · However, Syfovre's sales missed the Zacks Consensus Estimate of $162 million but slightly beat our model estimate of $151.7 million. Apellis delivered more than 84,500 …

tradingview.com

FAQs about Apellis drops as disappointing Syfovre sales drive Q3 miss - MSN Coupon?

How much syfovre did apellis pharmaceuticals deliver?

Apellis Pharmaceuticals delivered more than 84,500 commercial vials of Syfovre, which treats geographic atrophy, plus 4,000 samples. On a quarter-over-quarter basis, that's up 7%. Apellis blamed a higher gross-to-net adjustment during the quarter for the revenue miss. ...

Why did apellis pharmaceuticals (APLS) stock fall sharply?

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye disorder drug Syfovre fell short of forecasts. ...

Is the sell-off in apellis Pharmaceuticals shares 'overdone'?

Citi said it believes the sell-off in Apellis Pharmaceuticals ( NASDAQ: APLS) shares following the company’s Q1 earnings report is “overdone.” ...

How much did syfovre sell?

Syfovre sales beat our model estimate of $50 million. Apellis delivered more than 37,000 commercial vials and nearly 10,000 samples of Syfovre to doctors in the third quarter. As of Oct 5, 2023, the total number of vials of the drug delivered since launch was reportedly more than 100,000. ...

Did apellis's syfovre sales beat the consensus estimate in Q1?

The investment bank said Q1 sales of Apellis’s drug Syfovre beat the consensus estimate, but that “it appears the buyside expected more than an approximately 20% quarter-over-quarter bump, even given Q1 headwi... ...

Should you buy syfovre (apellis) in the GA market?

While the price target was adjusted from $95 to $60, the overall growth potential for Syfovre in the GA market contributes to Phil Nadeau’s Buy rating for Apellis Pharmaceuticals. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. ...